Can't Miss Webinar—Lupus Nephritis: The ACR Guideline in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

3 AC&R Study Summaries: RA & Frailty, Hydroxychloroquine Can Protect Kidneys in Lupus Nephritis, & PT for Knee OA

Arthritis Care & Research  |  Issue: November 2025  |  November 11, 2025

The study: Garg S, Rovin B, Astor BC, et al. Hydroxy­chloroquine associated with lower glomerular filtration rate decline in lupus nephritis. Arthritis Care Res (Hoboken). 2025 Jul 20. Epub ahead of print.

Referrals to PT for Managing Knee OA

By Samannaaz S. Khoja, PT, PhD, Joel M. Stevans, DC, PhD, Gustavo J. Almeida, PT, PhD, Clair Smith, MS, & Janet K. Freburger, PT, PhD

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Why was this study done? Physical therapy (PT) can be an impactful and cost-effective intervention during the early management of knee osteoarthritis (OA) and has been linked to better patient outcomes, lower opioid use and lower healthcare costs. Initial care of knee OA is largely driven by physicians, with patients mostly seeking PT through physician referrals. This study aimed to describe the frequency and timing of physician referrals to PT, and the frequency of other knee OA treatments prescribed over 12 months in patients with a recent knee OA diagnosis. We also examined patient, practice and physician factors associated with early PT referrals.

What were the study methods? This retrospective study used electronic medical records (EMR) from an integrated healthcare system. Visits for new onset of knee OA symptoms were identified using ICD-10 codes. Early PT referral was defined as a referral by the same physician within 15 days of the initial knee OA-related visit. EMR data included PT referrals, knee OA treatments, patient, physician and practice characteristics. We used a public dataset to obtain counts of licensed PTs within the counties where practices were located. We used generalized linear mixed models to examine factors associated with early PT referrals.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

What were the key findings? In patients with recent onset knee OA, 26% received at least one PT referral within 12 months, but only 17% received an early PT referral (within 15 days). Oral pain medications and therapeutic injections were among the most frequently prescribed treatments, while lifestyle counseling was among the least. Early PT referrals were less likely in those with higher or missing knee pain scores and those seen in rural practices, and more likely in women, patients with higher BMI and in counties with a greater number of PTs.

What were the main conclusions? Physician referrals to PT for early management of knee OA are infrequent and may be influenced by patient and practice factors.

What are the implications for patients and clinicians? Non-pharmacological knee OA approaches are underused, despite being recommended as frontline treatment in clinical practice guidelines. This study underscores the need to improve the access and delivery of PT and lifestyle interventions for knee OA.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:ConditionsGuidanceOsteoarthritis and Bone DisordersResearch RheumRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:AC&RArthritis Care & ResearchfrailtyHydroxychloroquine (HCQ)kidney diseaseknee osteoarthritisLupus nephritisPhysical TherapyReferral

Related Articles

    Lupus Nephritis: A Serious Manifestation of Systemic Lupus Erythematosus

    December 6, 2025

    This review highlights some of the many abstracts on lupus nephritis research presented at ACR Convergence 2025. They demonstrate advances made on early recognition of the condition, as well as offering some hope in terms of achieving better outcomes.

    Reading Rheum

    November 1, 2007

    Handpicked Reviews of Contemporary Literature

    Should Hydroxychloroquine Level Testing Be Standard Care in Lupus?

    February 13, 2020

    The Johns Hopkins Lupus Center, Baltimore, has described its experience using hydroxychloroquine (HCQ) levels.1 Forty-four percent of its patients had levels below 500 ng/mL (partial nonadherence); 13% were severely nonadherent (<200 ng/mL). They were shown their results and educated on HCQ adherence. Adherence then improved to 80%; those with lower HCQ levels had higher disease…

    New Study Probes Hydroxychloroquine Adherence During Pregnancy

    May 11, 2023

    Hydroxychloroquine (HCQ) is nearly universally recommended for pregnant patients with systemic lupus erythematosus (SLE) to reduce lupus disease activity and adverse outcomes in pregnancy.1-3 Yet despite strong evidence supporting its benefits, HCQ appears underutilized, with several studies suggesting fewer than half of all women with lupus take this medication during pregnancy.4 How accurately these results…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2026 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences